enVVeno Medical (enVVeno Medical) LT-Debt-to-Total-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. enVVeno Medical's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.02.

enVVeno Medical's long-term debt to total assets ratio declined from Mar. 2023 (0.04) to Mar. 2024 (0.02). It may suggest that enVVeno Medical is progressively becoming less dependent on debt to grow their business.

enVVeno Medical LT-Debt-to-Total-Asset Historical Data

The historical data trend for enVVeno Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical LT-Debt-to-Total-Asset Chart

enVVeno Medical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.17

0.02

0.03

0.02

enVVeno Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.02	0.02

enVVeno Medical LT-Debt-to-Total-Asset Calculation

enVVeno Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.064	/	48.635
	=

enVVeno Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0.973	/	44.829
	=

enVVeno Medical (NAS:NVNO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

enVVeno Medical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

enVVeno Medical (enVVeno Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

5HJ:Germany 5HJ:Germany

Address

70 Doppler, Irvine, CA, USA, 92618

Website

https://www.envveno.com

enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Executives

Hamed Alavi	officer: Chief Technology Officer	ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman	director, officer: CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis	director	2 GOODYEAR, IRVINE CA 92618
Robert Gray	director	70 DOPPLER, IRVINE CA 92618
Marc H. Glickman	officer: See Remarks	70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a.	10 percent owner	13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn	officer: Chief Financial Officer	70 DOPPLER, IRVINE CA 92618
Marcus W. Robins	director	C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin	officer: Chief Financial Officer	9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd	10 percent owner	P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle	director	70 DOPPLER, IRVINE CA 92618
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Susan Montoya	officer: See Remarks	70 DOPPLER, IRVINE CA 92618